Cargando…

Venous Thromboembolism Prophylaxis in Inflammatory Bowel Disease: A Two-year Retrospective Study of Patients Presenting With Inflammatory Bowel Disease to a Community Hospital

Objective We set out to determine the rate of pharmacological venous thromboembolism (VTE) prophylaxis among patients admitted with inflammatory bowel disease (IBD) and indirectly compare it to national trends. We also assessed the demographic and clinical correlates for non-prescription of pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales: Amakye, Dominic, Kesiena, Onoriode, Ademiluyi, Ademayowa, Gavor, Margaret, Rabeeah, Zahraa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568696/
https://www.ncbi.nlm.nih.gov/pubmed/36259017
http://dx.doi.org/10.7759/cureus.29178
_version_ 1784809693304061952
author Amakye, Dominic
Kesiena, Onoriode
Ademiluyi, Ademayowa
Gavor, Margaret
Rabeeah, Zahraa
author_facet Amakye, Dominic
Kesiena, Onoriode
Ademiluyi, Ademayowa
Gavor, Margaret
Rabeeah, Zahraa
author_sort Amakye, Dominic
collection PubMed
description Objective We set out to determine the rate of pharmacological venous thromboembolism (VTE) prophylaxis among patients admitted with inflammatory bowel disease (IBD) and indirectly compare it to national trends. We also assessed the demographic and clinical correlates for non-prescription of pharmacologic VTE prophylaxis among IBD patients with and without a flare. Methods We extracted data from 123 patients admitted to our facility with IBD from September 2018 to August 2020 retrospectively. Out of this cohort, 26 patients were excluded and 96 were included in our analysis. Baseline characteristics were analyzed using descriptive statistics. Multiple logistic regression was used to evaluate the correlates of pharmacological VTE prophylaxis use in individuals with IBD and to analyze the predictors of VTE prophylaxis use in patients with IBD flares. Results Out of the 96 patients with IBD included in this study, 61 (63.5%) presented with an IBD flare, and among those with a flare, 26/61 (42.6%) received VTE prophylaxis. IBD patients aged ≥ 65 years and of Black race were less likely to be placed on pharmacological VTE prophylaxis (adjusted odds ratio (AOR) 0.20, 95% CI (0.06 - 0.70), p-value 0.012) and (AOR 0.16, 95% CI (0.05 - 0.50), p-value 0.002) respectively. Among those with a flare, the presence of bright red bleeding per rectum was associated with a low rate of pharmacologic VTE use (AOR 0.01, 95% CI (0.00 -1.78), p-value 0.001). Overall the rate of VTE prophylaxis use in the IBD patient cohort was 56.3% and this was irrespective of flare status. Conclusion Our study showed the low rate of pharmacologic VTE prophylaxis use in IBD patients at this center and this finding was in line with national trends. Interestingly age and the race of patients played a major role in the decision to provide pharmacological VTE prophylaxis but the reason for this finding was not explored by our study. A larger multi-center study is needed to further evaluate these relationships.
format Online
Article
Text
id pubmed-9568696
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-95686962022-10-17 Venous Thromboembolism Prophylaxis in Inflammatory Bowel Disease: A Two-year Retrospective Study of Patients Presenting With Inflammatory Bowel Disease to a Community Hospital Amakye, Dominic Kesiena, Onoriode Ademiluyi, Ademayowa Gavor, Margaret Rabeeah, Zahraa Cureus Internal Medicine Objective We set out to determine the rate of pharmacological venous thromboembolism (VTE) prophylaxis among patients admitted with inflammatory bowel disease (IBD) and indirectly compare it to national trends. We also assessed the demographic and clinical correlates for non-prescription of pharmacologic VTE prophylaxis among IBD patients with and without a flare. Methods We extracted data from 123 patients admitted to our facility with IBD from September 2018 to August 2020 retrospectively. Out of this cohort, 26 patients were excluded and 96 were included in our analysis. Baseline characteristics were analyzed using descriptive statistics. Multiple logistic regression was used to evaluate the correlates of pharmacological VTE prophylaxis use in individuals with IBD and to analyze the predictors of VTE prophylaxis use in patients with IBD flares. Results Out of the 96 patients with IBD included in this study, 61 (63.5%) presented with an IBD flare, and among those with a flare, 26/61 (42.6%) received VTE prophylaxis. IBD patients aged ≥ 65 years and of Black race were less likely to be placed on pharmacological VTE prophylaxis (adjusted odds ratio (AOR) 0.20, 95% CI (0.06 - 0.70), p-value 0.012) and (AOR 0.16, 95% CI (0.05 - 0.50), p-value 0.002) respectively. Among those with a flare, the presence of bright red bleeding per rectum was associated with a low rate of pharmacologic VTE use (AOR 0.01, 95% CI (0.00 -1.78), p-value 0.001). Overall the rate of VTE prophylaxis use in the IBD patient cohort was 56.3% and this was irrespective of flare status. Conclusion Our study showed the low rate of pharmacologic VTE prophylaxis use in IBD patients at this center and this finding was in line with national trends. Interestingly age and the race of patients played a major role in the decision to provide pharmacological VTE prophylaxis but the reason for this finding was not explored by our study. A larger multi-center study is needed to further evaluate these relationships. Cureus 2022-09-15 /pmc/articles/PMC9568696/ /pubmed/36259017 http://dx.doi.org/10.7759/cureus.29178 Text en Copyright © 2022, Amakye et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Amakye, Dominic
Kesiena, Onoriode
Ademiluyi, Ademayowa
Gavor, Margaret
Rabeeah, Zahraa
Venous Thromboembolism Prophylaxis in Inflammatory Bowel Disease: A Two-year Retrospective Study of Patients Presenting With Inflammatory Bowel Disease to a Community Hospital
title Venous Thromboembolism Prophylaxis in Inflammatory Bowel Disease: A Two-year Retrospective Study of Patients Presenting With Inflammatory Bowel Disease to a Community Hospital
title_full Venous Thromboembolism Prophylaxis in Inflammatory Bowel Disease: A Two-year Retrospective Study of Patients Presenting With Inflammatory Bowel Disease to a Community Hospital
title_fullStr Venous Thromboembolism Prophylaxis in Inflammatory Bowel Disease: A Two-year Retrospective Study of Patients Presenting With Inflammatory Bowel Disease to a Community Hospital
title_full_unstemmed Venous Thromboembolism Prophylaxis in Inflammatory Bowel Disease: A Two-year Retrospective Study of Patients Presenting With Inflammatory Bowel Disease to a Community Hospital
title_short Venous Thromboembolism Prophylaxis in Inflammatory Bowel Disease: A Two-year Retrospective Study of Patients Presenting With Inflammatory Bowel Disease to a Community Hospital
title_sort venous thromboembolism prophylaxis in inflammatory bowel disease: a two-year retrospective study of patients presenting with inflammatory bowel disease to a community hospital
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568696/
https://www.ncbi.nlm.nih.gov/pubmed/36259017
http://dx.doi.org/10.7759/cureus.29178
work_keys_str_mv AT amakyedominic venousthromboembolismprophylaxisininflammatoryboweldiseaseatwoyearretrospectivestudyofpatientspresentingwithinflammatoryboweldiseasetoacommunityhospital
AT kesienaonoriode venousthromboembolismprophylaxisininflammatoryboweldiseaseatwoyearretrospectivestudyofpatientspresentingwithinflammatoryboweldiseasetoacommunityhospital
AT ademiluyiademayowa venousthromboembolismprophylaxisininflammatoryboweldiseaseatwoyearretrospectivestudyofpatientspresentingwithinflammatoryboweldiseasetoacommunityhospital
AT gavormargaret venousthromboembolismprophylaxisininflammatoryboweldiseaseatwoyearretrospectivestudyofpatientspresentingwithinflammatoryboweldiseasetoacommunityhospital
AT rabeeahzahraa venousthromboembolismprophylaxisininflammatoryboweldiseaseatwoyearretrospectivestudyofpatientspresentingwithinflammatoryboweldiseasetoacommunityhospital